BR112018073136A2 - métodos para tratar doença autoimune usando células t alogênicas - Google Patents

métodos para tratar doença autoimune usando células t alogênicas

Info

Publication number
BR112018073136A2
BR112018073136A2 BR112018073136-6A BR112018073136A BR112018073136A2 BR 112018073136 A2 BR112018073136 A2 BR 112018073136A2 BR 112018073136 A BR112018073136 A BR 112018073136A BR 112018073136 A2 BR112018073136 A2 BR 112018073136A2
Authority
BR
Brazil
Prior art keywords
methods
allogeneic
cells
autoimmune disease
treat autoimmune
Prior art date
Application number
BR112018073136-6A
Other languages
English (en)
Inventor
Khanna Rajiv
Original Assignee
The Council Of The Queensland Institute Of Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Council Of The Queensland Institute Of Medical Research filed Critical The Council Of The Queensland Institute Of Medical Research
Publication of BR112018073136A2 publication Critical patent/BR112018073136A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

a presente invenção refere-se a composições compreendendo células citotóxicas t alogênicas que expressam um receptor de célula t que se liga especificamente a um peptídeo do vírus de epstein-barr (ebv) apresentado em uma mhc de classe i e métodos para tratamento de doenças autoimunes com esta composição.
BR112018073136-6A 2016-05-25 2017-05-25 métodos para tratar doença autoimune usando células t alogênicas BR112018073136A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662341360P 2016-05-25 2016-05-25
US62/341,360 2016-05-25
US201662359326P 2016-07-07 2016-07-07
US62/359,326 2016-07-07
US201762487814P 2017-04-20 2017-04-20
US62/487,814 2017-04-20
PCT/IB2017/000805 WO2017203368A1 (en) 2016-05-25 2017-05-25 Methods of treating autoimmune disease using allogeneic t cells

Publications (1)

Publication Number Publication Date
BR112018073136A2 true BR112018073136A2 (pt) 2019-03-12

Family

ID=60411139

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018073136-6A BR112018073136A2 (pt) 2016-05-25 2017-05-25 métodos para tratar doença autoimune usando células t alogênicas

Country Status (14)

Country Link
US (2) US20210220402A1 (pt)
EP (1) EP3463399A4 (pt)
JP (2) JP7136701B2 (pt)
KR (2) KR20190030661A (pt)
CN (1) CN109475578A (pt)
AU (2) AU2017271134A1 (pt)
BR (1) BR112018073136A2 (pt)
CA (1) CA3024277A1 (pt)
CL (1) CL2018003284A1 (pt)
IL (1) IL262989A (pt)
MX (1) MX2018013959A (pt)
PH (1) PH12018502402A1 (pt)
SG (1) SG11201809534UA (pt)
WO (1) WO2017203368A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
ES2928851T3 (es) 2012-02-09 2022-11-23 Baylor College Medicine Mezclas pep para generar CTL multivíricos con amplia especificidad
JP6999941B2 (ja) 2015-09-18 2022-02-10 ベイラー カレッジ オブ メディスン 病原体からの免疫原性抗原同定および臨床的有効性との相関
NZ749136A (en) 2016-05-25 2023-11-24 Council Queensland Inst Medical Res Methods of immunotherapy
JP2020506901A (ja) * 2017-01-20 2020-03-05 アタラ バイオセラピューティクス，インコーポレーテッド 自家ｔ細胞を用いた多発性硬化症の処置方法
EP3737394A4 (en) * 2018-01-08 2021-11-10 Atara Biotherapeutics, Inc. SYSTEMS AND METHODS FOR DISTRIBUTION OF CELL THERAPIES
JP2021526826A (ja) * 2018-06-13 2021-10-11 ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ ウイルス検出アッセイ
EP3922642A4 (en) * 2019-02-08 2023-03-29 Good T Cells, Inc. METHOD OF ACTIVATING T LYMPHOCYTES FOR THE TREATMENT OF CANCER
BR112022001596A2 (pt) * 2019-07-29 2022-06-07 Baylor College Medicine Bancos de células t específicas para antígeno e métodos para produzir e usar os mesmos terapeuticamente

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO784197A0 (en) * 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
US20030147865A1 (en) * 2002-02-07 2003-08-07 Benoit Salomon Cell therapy using immunoregulatory T-cells
US20090324630A1 (en) * 2008-04-21 2009-12-31 Jensen Michael C Fusion multiviral chimeric antigen
EP4285922A1 (en) * 2011-05-26 2023-12-06 Geneius Biotechnology Investments, LLC Modulated immunodominance therapy
AU2012351347B2 (en) * 2011-12-12 2016-05-19 Baylor College Of Medicine Process of expanding T cells
CN104491857B (zh) * 2014-12-24 2018-08-31 深圳市中美康士生物科技有限公司 一种用于免疫治疗ebv相关疾病的抗原组合物、生物制剂及其制备方法

Also Published As

Publication number Publication date
JP7136701B2 (ja) 2022-09-13
EP3463399A4 (en) 2020-03-18
EP3463399A1 (en) 2019-04-10
AU2017271134A1 (en) 2019-01-03
JP2019516751A (ja) 2019-06-20
RU2018145500A3 (pt) 2020-10-15
CL2018003284A1 (es) 2019-06-14
CA3024277A1 (en) 2017-11-30
PH12018502402A1 (en) 2019-04-08
RU2018145500A (ru) 2020-06-25
JP7454617B2 (ja) 2024-03-22
SG11201809534UA (en) 2018-12-28
WO2017203368A1 (en) 2017-11-30
KR20230113817A (ko) 2023-08-01
IL262989A (en) 2018-12-31
CN109475578A (zh) 2019-03-15
AU2024204831A1 (en) 2024-08-01
KR20190030661A (ko) 2019-03-22
JP2022174151A (ja) 2022-11-22
MX2018013959A (es) 2019-08-22
US20210220402A1 (en) 2021-07-22
US20220409662A1 (en) 2022-12-29

Similar Documents

Publication Publication Date Title
BR112018073136A2 (pt) métodos para tratar doença autoimune usando células t alogênicas
BR112019007100A2 (pt) composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
BR112017005390A2 (pt) células citotóxicas alvo com receptores quiméricos para imunoterapia adotiva
CO2017000506A2 (es) Receptor quimérico de antígeno cll-1
BR112019001570A2 (pt) terapias de combinação de receptores de antígeno quiméricos e inibidores de pd-1
CO2018001149A2 (es) Anticuerpos monoclonales contra bcma
CO2017001573A2 (es) Receptor quimérico de antígeno anti-cd123
BR112019006781A2 (pt) receptores de antígeno quiméricos para o tratamento de câncer
CL2017001515A1 (es) Receptores de antígeno químericos bcma
ECSP19031545A (es) Composiciones de células t con car anti-bcma
CO2017000507A2 (es) Receptor quimérico de antígeno bcma
CR20150664A (es) Moduladores de los receptores de estrógeno y sus usos
MX2017014822A (es) Composiciones y métodos para la reprogramación del tcr con proteínas de fusión.
CL2020001181A1 (es) Nuevos receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos.
BR112017001242A2 (pt) tratamento de câncer usando um receptor antigênico quimérico a cd33
BR112019022321A2 (pt) Tcr e peptídeos
BR112016022727A8 (pt) imunorreceptores específicos de claudina-6 e epítopos de células t
BR112016013187A2 (pt) receptores de antígenos quiméricos de mesotelina humanos e usos dos mesmos
SG10201900455YA (en) Bcma chimeric antigen receptors
CL2018000750A1 (es) Método de redireccionamiento de linfocitos t para el tratamiento de la infección por vih
CL2019003270A1 (es) Carboxamidas de octa hidrofenantreno - bis y conjugados de proteína.
BR112019021857A2 (pt) Métodos e composições de célula t aperfeiçoada
BR112014010532A2 (pt) anticorpo e métodos para inibição seletiva de respostas de célula-t
BR112021006280A2 (pt) terapias imunoablativas
BR112013002831A2 (pt) anticorpos direcionados contra a il-17

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DAS PRIORIDADES US 62/359,326, US 62/341,360 E US 62/487,814 REIVINDICADAS NO PCT/IB2017/000805, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O E ART 2O DA RESOLUCAO INPI 179 DE 21/02/2017. ESTA PERDA SE DEU PELO FATO DE O DEPOSITANTE CONSTANTE DA PETICAO DE REQUERIMENTO DO PEDIDO PCT (THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH ) SER DISTINTO DAQUELES QUE DEPOSITARAM AS PRIORIDADES REIVINDICADAS E NAO APRESENTOU DOCUMENTO COMPROBATORIO DE CESSAO DENTRO DO PRAZO DE 60 DIAS A CONTAR DA DATA DA ENTRADA DA FASE NACIONAL, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 6O, E NO ART. 28 DA RESOLUCAO INPI-PR 77/2

B12F Other appeals [chapter 12.6 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]